Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ligand Pharmaceuticals

114.07
-0.5700-0.50%
Post-market: 114.070.00000.00%16:16 EDT
Volume:259.23K
Turnover:29.54M
Market Cap:2.20B
PE:-16.05
High:114.94
Open:114.94
Low:112.42
Close:114.64
Loading ...

Dow Falls Over 1%; US Initial Jobless Claims Decline

Benzinga
·
17 Apr

Ligand to Combine Pelthos Unit With Channel Therapeutics

Dow Jones
·
17 Apr

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

MT Newswires Live
·
17 Apr

BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics

Reuters
·
17 Apr

Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics

THOMSON REUTERS
·
17 Apr

Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO

THOMSON REUTERS
·
17 Apr

Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital

THOMSON REUTERS
·
17 Apr

Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on Nyse American Exchange Under Ticker Pths

THOMSON REUTERS
·
17 Apr

Channel Therapeutics Corp - Ligand Is Entitled to a 13% Royalty on Worldwide Sales of Zelsuvmi

THOMSON REUTERS
·
17 Apr

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

GlobeNewswire
·
17 Apr

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Benzinga
·
17 Apr

BUZZ-U.S. STOCKS ON THE MOVE-AppLovin, Ligand Pharma, Dexcom

Reuters
·
11 Apr

BUZZ-Stifel starts coverage on Ligand Pharma with 'buy'

Reuters
·
10 Apr

Ligand Pharmaceuticals Inc : Stifel Initiates Coverage With Buy Rating; Price Target $143

THOMSON REUTERS
·
10 Apr

Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target

MT Newswires Live
·
10 Apr

Ligand initiated with a Buy at Stifel

TIPRANKS
·
10 Apr

Ligand Pharmaceuticals FY 2024 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027

Benzinga
·
31 Mar

Press Release: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
31 Mar

Barclays Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
10 Mar

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

Simply Wall St.
·
08 Mar